Welcome to our dedicated page for Soleno Therapeutics SEC filings (Ticker: SLNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Soleno Therapeutics, Inc. (NASDAQ: SLNO) provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Soleno describes itself as a biopharmaceutical company focused on novel therapeutics for rare diseases, and its filings document financial results, material agreements, governance changes, and other significant events related to this business.
Investors can review current reports on Form 8-K in which Soleno announces quarterly and preliminary financial results, operating metrics for VYKAT XR (diazoxide choline) extended-release tablets, and updates on the U.S. launch of this once-daily oral treatment for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome. These filings incorporate press releases that discuss product revenue, profitability, cash balances, and other financial information.
Filings also describe capital structure and financing arrangements, including an accelerated share repurchase (ASR) Agreement with Jefferies LLC for up to $100 million of common stock and a first amendment to Soleno’s loan and security agreement with Oxford Finance LLC and other lenders. The 8-Ks outline key terms of these arrangements, such as prepayment of the purchase price, initial share delivery, and changes to loan availability.
Additional 8-Ks cover corporate governance and Board composition, such as the appointment of an independent director with extensive biopharmaceutical finance experience and the associated equity grants under the company’s equity incentive plan. Other filings provide Regulation FD disclosures on topics like investor presentations and safety-related communications, including Soleno’s description of a serious adverse event reported in the FDA’s FAERS database and its assessment of that event.
On this page, AI-powered tools can help summarize lengthy exhibits and press releases attached to Soleno’s filings, highlight key terms in material agreements, and clarify the implications of reported financial metrics, capital transactions, and governance changes for users reviewing SLNO’s regulatory history.
Soleno Therapeutics, Inc. appointed Jennifer Fulk as Chief Financial Officer, succeeding retiring CFO James Mackaness. Her start date is expected to be March 2, 2026, with Mackaness remaining through March 31, 2026 and then consulting through year-end to support a smooth transition.
Fulk’s employment terms include a $525,000 annual base salary, eligibility for a target cash bonus equal to 45% of base salary, an option to purchase 67,660 shares of common stock, and 39,200 restricted stock units, each subject to multi‑year vesting and continued service.
Soleno Therapeutics reports its first year as a commercial-stage company after FDA approval of VYKAT XR for hyperphagia in Prader-Willi syndrome on March 26, 2025. The company began recognizing product revenue in the quarter ended June 30, 2025 and generated net income of
VYKAT XR is the first U.S. treatment specifically approved for PWS-related hyperphagia, targeting ATP-sensitive potassium channels to reduce appetite and improve metabolic parameters. Soleno is commercializing the drug with a specialized 65-person field force at a list price of
Soleno Therapeutics reported a rapid shift to commercial growth driven by its first product, VYKAT XR for Prader‑Willi syndrome. Product revenue, net, reached $91.7 million in the fourth quarter and $190.4 million for 2025, compared to no product revenue in 2024.
For 2025, the company generated net income of $20.9 million, or $0.40 per basic share, reversing a $175.9 million net loss in 2024. Operating income was $9.4 million for the year as higher sales offset commercialization costs.
Research and development expense fell to $40.6 million for 2025 from $78.6 million, mainly as pre‑launch and clinical costs declined. Selling, general and administrative expense increased to $132.1 million, reflecting commercial hiring, launch programs and international expansion.
Soleno reported strong launch momentum, noting patient start forms representing over 12% of the U.S. VYKAT XR addressable market in nine months. Total assets were $563.8 million and stockholders’ equity was $450.1 million as of December 31, 2025.
Janus Henderson Group plc filed an amended ownership report showing it is the beneficial owner of 7,178,354 shares of Soleno Therapeutics, Inc. common stock, representing 13.4% of the class as of the reported date.
The shares are held through various Janus Henderson asset management subsidiaries in managed client accounts, giving them shared power to vote and dispose of these shares but no sole authority. The managed portfolios receive all dividends and sale proceeds, and no individual portfolio holds more than five percent of Soleno’s common stock.
Soleno Therapeutics Inc. (SLNO) received a new 5.4% passive ownership disclosure from Avoro Capital Advisors LLC and Behzad Aghazadeh. The investors report beneficial ownership of 2,900,000 shares of Soleno common stock, based on 53,710,025 shares outstanding as of October 31, 2025.
Avoro, an investment adviser, states that the shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC. The filing certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Soleno. Both Avoro and Dr. Aghazadeh report sole voting and dispositive power over the 2,900,000 shares.
Wellington Management Group and affiliates report a significant ownership position in Soleno Therapeutics, Inc. They beneficially own 3,322,799 shares of Soleno common stock, representing 6.19% of the class as of December 31, 2025.
The Wellington entities report zero sole voting or dispositive power, with all voting and investment authority shared across group entities. The shares are owned of record by clients of various Wellington investment advisers, and no single client is reported to hold more than five percent of the class. The position is certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Soleno.
Soleno Therapeutics reported new equity awards for officer Kristen Yen, its SVP Global Clinical Operations and Patient Advocacy. On January 21, 2026, Yen received 10,400 shares of Common Stock for no cash cost, structured as restricted stock units. These RSUs are scheduled to vest 100% on December 15, 2027, if she continues as a service provider under the company’s 2014 Equity Incentive Plan.
Yen also received an employee stock option covering 11,900 shares of Common Stock at an exercise price of $43.65 per share. This option begins vesting on February 1, 2026, with 1/48th of the shares vesting monthly thereafter, contingent on continued service. After these transactions, she beneficially owned 37,639 shares of Common Stock directly, along with 11,900 stock options.
Soleno Therapeutics executive Kevin Norrett reported new equity awards in the form of restricted stock units and stock options. On January 21, 2026, he received 3,500 restricted stock units of Common Stock at no cost, bringing his beneficial ownership to 17,786 RSUs representing shares of Common Stock. These RSUs are scheduled to vest 100% on December 15, 2027, as long as he continues as a service provider under the company’s 2014 Equity Incentive Plan.
On the same date, he was also granted an employee stock option to purchase 4,000 shares of Common Stock at an exercise price of $43.65 per share. This option vests in equal monthly installments, with 1/48th of the shares vesting on February 1, 2026 and on each monthly anniversary thereafter, subject to his continued service. Both awards are standard compensation arrangements that align his interests with long-term company performance.
Soleno Therapeutics’ Chief Commercial Officer Manning Meredith received new equity awards. On January 21, 2026, Meredith was granted 28,600 shares of Common Stock in the form of restricted stock units at a grant price of $0. These RSUs are scheduled to vest 100% on December 15, 2027, as long as Meredith continues as a service provider under the company’s 2014 Equity Incentive Plan.
On the same date, Meredith was also granted an employee stock option for 32,800 shares of Common Stock with an exercise price of $43.65 per share. One forty‑eighth of these option shares will vest on February 1, 2026, with additional vesting on each monthly anniversary, subject to continued service. After these transactions, Meredith beneficially owned 72,029 shares of Common Stock directly, including RSUs subject to vesting conditions.
Soleno Therapeutics reported that its Chief Financial Officer, James H. Mackaness, received equity awards on January 21, 2026. He was granted 28,600 shares of Common Stock in the form of restricted stock units (RSUs) at a price of
On the same date, he also received an employee stock option for 32,800 shares of Common Stock at an exercise price of